Qualigen is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as the expansion of its flagship FastPack® diagnostic platform. The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002. Our therapeutics pipeline includes cancer drug candidate compounds such as AS1411, ALAN, the RAS-F family of drug candidate compounds, as well as STARS, a DNA/RNA-based treatment device. By combining our demonstrated ability to quickly develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, such as the University of Louisville, we are committed to providing exciting new therapeutic technologies to physicians and patients.
Qualigen’s AS1411 cancer drug candidate uses synthetic DNA, known as an aptamer, to target and destroy tumor cells, without the serious side effects associated with other cancer therapies. In addition, in vitro studies recently performed at the University of Louisville demonstrated that AS1411 may protect cells from the harmful effects of SARS-CoV-2 infection (COVID-19).
Our ALAN cancer drug candidate combines the AS1411 DNA aptamer with gold nanoparticle technology to increase its potency and broaden its potential applications to include combination therapy with radiation, tumor imaging and as a delivery system for other anti-cancer drug compounds.
The STARSTM device will use DNA aptamer technology to potentially cleanse a patient’s blood of circulating viruses, tumor cells, inhibitory checkpoints and inflammation factors. STARS can also be used for infectious disease treatment, where it can capture and remove viruses.
RAS-F is a family of small-molecule cancer drug candidates that are designed to inhibit a genetic mutation that can turn a normal cell into a tumor cell. These mutations occur in many different cancer types, including pancreatic, lung and colorectal.
The company’s flagship product line, FastPack®, combines magnetic particle immunochemistry with innovative disposable packaging technology to provide real-time diagnostic information for cancers and other serious medical conditions.
Qualigen Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference
Posted on Tuesday January 05, 2021
Qualigen Therapeutics Issues CEO Letter to Stockholders with 2021 Outlook
Posted on Tuesday December 22, 2020
Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering
Posted on Friday December 18, 2020